PolyPeptide follows an integrated approach for the management of environmental, social and governance (ESG) topics that are considered material for its business. As a contract development and manufacturing organization (CDMO) serving pharma and biotech customers, PolyPeptide must adhere to stringent product quality requirements and regulations to protect the safety of patients. The Group seeks to promote corporate responsibility and to follow fundamental principles of business ethics and compliance.

PolyPeptide believes that the integration of material ESG topics into its strategy, operations and enterprise risk management framework is the most effective way to meet its business needs and stakeholder expectations. It uses a set of quantitative metrics to manage relevant ESG impacts, risks and opportunities, and to track its impact and progress on sustainable development.

For further information regarding PolyPeptide’s strategy, market and business model, see section Strategy.

This Corporate Responsibility Report covers the period 1 January 2023 to 31 December 2023 (unless otherwise stated). It has been prepared in accordance with art. 964b of the Swiss Code of Obligations (CO) concerning transparency on non-financial matters (see section 5 Disclosures in accordance with art. 964b Swiss Code of Obligations), presents the Group’s first report with reference to the GRI Standards (see section 7 GRI content index) and will be updated annually.